Virology & Mycology
Open Access
ISSN: 2161-0517
+44 1223 790975
ISSN: 2161-0517
+44 1223 790975
Sumit Sahu1 and Sneha Shekhar2
Posters-Accepted Abstracts: Virol-mycol
DNA and RNA based genetic vaccines are now considered as developed. This is lower in cost and effective at the same time which is extensively used for various cancer therapies, ancestral allergies and various infections and chronic diseases such as seasonal flu like bird flu, swine flu, equine flu etc. With all these advantages there are certain limitations for these genetic vaccines which might be the major drawback for its commercial growth and animal trials. The major limitation is delivery of DNA vaccines to the target sites which need to develop carrier molecules for delivering vaccines into immunized individuals. Because of lack of carrier molecules results in low intracellular presence of vaccine encoding as antigen thus low expression level which in turn reduces immune response against the target antigen. By the improvement of DNA delivery technology we can significantly increase effectiveness of genetic vaccines. Various mechanical methods like jet injections, carrier molecule (lipids, proteins etc.), electroporation, micro-needles etc are being used. Other methods are also popular among which most common are peptides, prime-boost with plasmid DNA and monovalent-inactivated vaccines. Using adjuvants of anti-influenza DNA vaccines and PCR generated complementary anti-RNA sequencing to block influenza virus expression are also popular. Researchers are focusing on DNA vaccines and are employing many strategies to fight against influenza.